ED
ARCT icon

Exane Derivatives’s Arcturus Therapeutics ARCT Stock Holding History

Exane Derivatives’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,652
Closed -$68.2K – 1048
2021
Q1 		$68.2K Buy
+1,652
New +$98.5K 0.02% 480

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Exane Derivatives's ARCT Position: Q2 2021 in Review

Exane Derivatives sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 1,652 shares — an estimated $68.2K sold.

Exane Derivatives first reported a position in ARCT in Q1 2021 and held it in 1 quarter. The position peaked at $68.2K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

  • Exane Derivatives reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Exane Derivatives sold 1,652 Arcturus Therapeutics shares in Q2 2021, an estimated $68.2K.
  • Exane Derivatives first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Exane Derivatives's Arcturus Therapeutics position peaked at $68.2K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.